Biolibra Formulations Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.43 M
- Company Age 13 Year, 3 Months
- Last Filing with ROC 31 Mar 2022
- Revenue Growth %
- Ebitda
- Net Worth
- Total Assets 3.30%
About Biolibra Formulations
Biolibra Formulations Private Limited (BFPL) is a Private Limited Indian Non-Government Company incorporated in India on 25 October 2011 and has a history of 13 years and three months. Its registered office is in Visakhapatnam, Andhra Pradesh, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.43 M, as per Ministry of Corporate Affairs (MCA) records.
Golagani Jyothi, Ashok Golagani, and Peethala Sudhakar serve as directors at the Company.
Company Details
-
Location
Visakhapatnam, Andhra Pradesh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24232AP2011PTC077149
-
Company No.
077149
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
25 Oct 2011
-
Date of AGM
30 Sep 2022
-
Date of Balance Sheet
31 Mar 2022
-
Listing Status
Unlisted
-
ROC Code
Roc Vijayawada
Industry
Who are the key members and board of directors at Biolibra Formulations?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Golagani Jyothi
|
Director | 25-Oct-2011 | Current |
|
Ashok Golagani
|
Director | 25-Oct-2011 | Current |
|
Peethala Sudhakar
|
Director | 25-Oct-2011 | Current |
Financial Performance of Biolibra Formulations.
Biolibra Formulations Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Biolibra Formulations?
In 2017, Biolibra Formulations had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Kumar Hospitals Private LimitedGolagani Jyothi and Ashok Golagani are mutual person
-
Kumar It Solutions Private LimitedGolagani Jyothi and Ashok Golagani are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Biolibra Formulations?
Unlock and access historical data on people associated with Biolibra Formulations, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Biolibra Formulations, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Biolibra Formulations's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
